NY-AB-INBEV
Today, Danone has joined AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), The Coca-Cola Company, Colgate-Palmolive Company, and Unilever as the fifth partner in the 100+ Accelerator, the groundbreaking program dedicated to pioneering sustainable innovation across global supply chains.
Launched in 2018 by AB InBev, the 100+ Accelerator has rapidly become a cornerstone initiative for catalyzing environmental stewardship and sustainable business practices through global collaboration and groundbreaking solutions in critical areas such as water stewardship, circular economy, sustainable agriculture, and climate action. In 2021, the 100+ Accelerator welcomed its first three partners to expand this unique approach to innovation and to further establish the value proposition of the program’s brand and mission. To date, it has accelerated 148 companies in 38 countries.
“Sustainability is core to our business strategy and fulfills our purpose of dreaming big to create a future with more cheers,” said Ingrid De Ryck, Chief Sustainability Officer of AB InBev. “In the 5 years since its launch, the 100+ Accelerator has helped us identify and scale solutions to business challenges, advance our 2025 sustainability goals and improve resilience across supply chains. We welcome Danone as a strategic partner in the 100+ Accelerator and are excited to continue developing the program’s impact through industry collaboration.”
“Our combined global reach will undoubtedly propel the 100+ Accelerator to new heights, driving broader adoption of sustainable innovations that will benefit our planet, our communities and our future.” Vikram Agarwal, Chief Operations Officer, Danone, also expressed his enthusiasm for the partnership: "This collaboration with 100+ Accelerator is yet another milestone in Danone's sustainability journey and is a direct result of our Partner For Growth program. It shows our commitment to working with all partners across our ecosystem to leverage our respective strengths to create shared value. With 100+ Accelerator, start-ups will be able to harness our internal resources to scale-up innovation that will deliver tangible environmental benefits across the value chain.”
Isabelle Esser, Danone Chief Research, Innovation, Quality and Food Safety Officer added, “We are proud to join the 100+ Accelerator program, which is fully aligned with our ambition to drive sustainable innovation for the future of our planet and our consumers. At Danone, we believe that strong partnerships are essential to help us stay one step ahead of global challenges, while continuing to honor our mission of shaping the food of tomorrow.”
The program's effectiveness is evidenced by its impact:
- Implementation of a range of technologies that help improve water efficiency including nanotechnology, electrochemistry and spectroscopy.
- Enhanced traceability and support systems for smallholder farmers, endeavoring to improve livelihoods and agricultural sustainability across continents.
- Fleet optimization including EV retrofitting, hydrogen co-fueling, aerodynamic solutions and hybrid charging.
- New cooling applications including thermodynamic coatings and magnetic refrigeration.
- Bio-based, compostable packaging alternatives or additives from banana fiber, spent grain, corn husk, bacterial nano-cellulose among others.
Applications for the sixth cohort of the accelerator will open on May 30. Forward-thinking entrepreneurs are invited to apply at www.100accelerator.com.
With the collective capabilities of AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever, the 100+ Accelerator will continue to scale innovative solutions to create a more sustainable world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529855383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom